Additional file 1: of Efficacy and safety of antagonists for chemoattractant receptor-homologous molecule expressed on Th2 cells in adult patients with asthma: a meta-analysis and systematic review

Figure S1. Beggâ s test for publication bias on pre-bronchodilator FEV1 (L). Figure S2. Meta-regression plot of mean difference for pre-bronchodilator FEV1 (L) predicted by treatment duration. Figure S3. Meta-regression plot of mean difference for pre-bronchodilator FEV1 (L) predicted by asthma severity. Figure S4. Meta-regression plot of mean difference for pre-bronchodilator FEV1 (L) predicted by concomitant treatment. Figure S5. The effect of CRTH2 antagonists used as monotherapy or add-on therapy versus placebo on pre-bronchodilator FEV1% predicted. Figure S6. The effect of CRTH2 antagonists used as monotherapy or add-on therapy versus placebo on post-bronchodilator FEV1 (L). Figure S7. The effect of CRTH2 antagonists used as monotherapy or add-on therapy versus placebo on FVC. Figure S8. The effect of CRTH2 antagonists used as monotherapy or add-on therapy versus placebo on severe adverse events. Figure S9. The effect of CRTH2 antagonists used as monotherapy or add-on therapy versus placebo on treatment related adverse events. Figure S10. The effect of CRTH2 antagonists used as monotherapy or add-on therapy versus placebo on adverse events leading to treatment withdrawal. Figure S11. Beggâ s test for publication bias on adverse event. Figure S12. Meta-regression plot of risk ratio for adverse events predicted by treatment duration. Figure S13. Meta-regression plot of risk ratio for adverse events predicted by concomitant treatment. Figure S14. Meta-regression plot of risk ratio for adverse events predicted by asthma severity. (DOCX 10650 kb)